|Last Price||Today's Change||52-Week Range||Trading Volume|
|59.88||-2.09 (-3.37%)||47.55 - 70.54||9.9 million|
Market data as of 4:01PM 10/06/15. Quotes are delayed by at least 15 min.
U.S. FDA Grants Priority Review For Daklinza (daclatasvir) sNDAs
10/06/2015 7:00 AM ET
Bristol-Myers Squibb Receives Approval from the U.S. Food and Drug Administration for the Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen in BRAF V600 Wild-Type Unresectable or Metastatic Melanoma
10/01/2015 6:59 AM ET